Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19083713 | METHOD FOR PREPARING HEMOGENIC ENDOTHELIUM CELL AND METHOD FOR PREPARING HEMATOPOIETIC STEM CELL OR HEMATOPOIETIC STEM AND PROGENITOR CELL | March 2025 | December 2025 | Allow | 9 | 1 | 0 | No | No |
| 19050950 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | February 2025 | December 2025 | Allow | 11 | 1 | 0 | No | No |
| 18873580 | STAGED CULTURE METHOD FOR IN-VITRO EXPANSION OF HUMAN CYTOKINE-INDUCED KILLER (CIK) AND USE THEREOF | December 2024 | August 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18948694 | RECOMBINANT AAV VECTORS FOR TREATING GLUTARIC ACIDURIA TYPE I | November 2024 | August 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18919051 | ANTIGEN BINDING POLYPEPTIDES | October 2024 | May 2025 | Abandon | 6 | 0 | 1 | Yes | No |
| 18849551 | MODIFIED VECTOR, CONSTRUCTION METHOD, AND APPLICATION OF MODIFIED AAV-8 SEROTYPE FOR GENE TARGETING AND EXPRESSION | September 2024 | February 2026 | Allow | 17 | 2 | 1 | No | No |
| 18891235 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | January 2026 | Allow | 15 | 3 | 0 | No | No |
| 18827471 | GENE THERAPY FOR SPINAL MUSCULAR ATROPHY | September 2024 | July 2025 | Allow | 11 | 1 | 1 | No | No |
| 18841165 | MODIFIED CPG DINUCLEOTIDES FOR RECOMBINANT VIRAL VECTOR PRODUCTION | August 2024 | August 2025 | Allow | 12 | 1 | 1 | No | No |
| 17635170 | Chimeric Antigen Receptor, Construction Method Therefor and Application Thereof | July 2022 | March 2026 | Abandon | 49 | 0 | 1 | No | No |
| 17811855 | OPTOGENETIC COMPOSITIONS COMPRISING A CBh PROMOTER SEQUENCE AND METHODS FOR USE | July 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17792100 | ADENO ASSOCIATED VIRUS BASED GENE THERAPY FOR PHENYLKETONURIA | July 2022 | January 2026 | Abandon | 42 | 1 | 1 | No | No |
| 17775767 | METHOD OF ISOLATION OF CULTURE OF VASCULAR ENDOTHELIAL CELLS, MEDIUM FOR MAINTAINING CHARACTERISTICS OF VASCULAR ENDOTHELIAL CELLS, AND CULTURE METHOD INCLUDING SAME | May 2022 | June 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 15733246 | ADENO-ASSOCIATED VIRUS (AAV) VECTOR LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF USE | March 2022 | December 2025 | Abandon | 60 | 2 | 0 | No | No |
| 17753710 | Anti CD70 CAR-T Cell, and Preparation Method Therefor and Use Thereof | March 2022 | June 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17639565 | METHOD FOR PRODUCING FROZEN BODY OF THREE-DIMENSIONAL TISSUE AGGREGATE OF RETINAL PIGMENT EPITHELIAL CELLS | March 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17683931 | VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES | March 2022 | December 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17635109 | METHOD FOR OBTAINING EFFICIENT COMPOSITIONS COMPRISING VIRAL VECTORS FOR VACCINATION OR GENE THERAPY | February 2022 | August 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17633769 | AAV CAPSID VARIANTS FOR TARGETING HUMAN GLIOBLASTOMA CELLS | February 2022 | January 2026 | Allow | 47 | 1 | 1 | No | No |
| 17629686 | COMPOSITION OF PHARMACEUTICAL CARRIER SOLUTION FOR MESENCHYMAL STEM CELLS AND USE OF THE SAME | January 2022 | September 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17625587 | Method for Promoting Cell Proliferation, and Method for Preparing Cell Cluster | January 2022 | February 2026 | Abandon | 49 | 2 | 1 | No | No |
| 17624584 | METHOD FOR IN-VITRO PRODUCTION OF MAMMALIAN NEURONS | January 2022 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17624200 | RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENCITY AND METHODS OF MAKING THE SAME | December 2021 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17620993 | NONHUMAN ANIMAL AND USE FOR SAME | December 2021 | September 2025 | Allow | 45 | 1 | 1 | No | No |
| 17602170 | METHOD FOR INDUCING DIRECT REPROGRAMMING OF URINE CELL INTO RENAL PROGENITOR CELL AND PHARMACEUTICAL COMPOSITION CONTAINING REPROGRAMMED RENAL PROGENITOR CELL | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17601812 | THERAPEUTIC PARTICLES THAT ENABLE ANTIGEN PRESENTING CELLS TO ATTACK CANCER CELLS | October 2021 | February 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17389169 | CYCLOPHILIN 40 FOR REDUCTION OF NEUROTOXIC FIBRILS AND TREATMENT OF NEURODEGENERATIVE DISEASES | July 2021 | November 2025 | Allow | 51 | 2 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ABBOTT, KODYE LEE works in Art Unit 1634 and has examined 6 patent applications in our dataset. With an allowance rate of 33.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner ABBOTT, KODYE LEE's allowance rate of 33.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ABBOTT, KODYE LEE receive 1.17 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ABBOTT, KODYE LEE is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +80.0% benefit to allowance rate for applications examined by ABBOTT, KODYE LEE. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.